You are here

P&T News

December 12

Manufacturer used FDA’s 505(b)(2) abbreviated approval pathway
This is the first drug for patients with eosinophilic granulomatosis with polyangiitis
Industry will provide funding for programs in partnership with Addiction Policy Forum
Platform offers advanced technology to treat symptoms of Parkinson’s disease

December 11

Four in 10 remain in complete remission, updated data show
Patients with high PD-L1 level show benefit in first-line treatment
Pfizer launches generic to counteract Teva’s version

December 7

Tecentriq was combined with Avastin and chemotherapy as initial treatment
First new drug approach to depression in two decades, company says
Six million affected today, 15 millions four decades from now

December 6

Once-weekly GLP-1 receptor agonist to be available in early 2018

December 5

Setback follows announcement of adverse patient outcomes with dengue vaccine
New technology would allow oral dosing of drugs typically administered by injection
Agency aims to reduce the cost of expensive drugs and treatments
New study confirms a dramatic decrease in infant deaths
RT002 met primary and all secondary endpoints in pivotal trials for glabellar lines

December 4

Merger partners say they’ll be able to push down drug costs
Second approved indication for Taltz in the United States
Evolocumab is the first PCSK9 Inhibitor to win this indication

Pages